Myonexus Therapeutics is a clinical-stage biotechnology company developing transformative gene therapies for limb-girdle muscular dystrophies (LGMDs). Its pipeline comprises five programs: MYO-101 (LGMD2E), MYO-102 (LGMD2D), MYO-201 (LGMD2B), MYO-103 (LGMD2C) and MYO-301 (LGMD2L), with MYO-102 completing a Phase 1/2a study and MYO-201 in Phase 1 while MYO-103 and MYO-301 are preclinical. The company plans to initiate a systemic Phase 1/2a clinical trial of MYO-101 in early 2018. The programs were pioneered in the lab of Louise Rodino-Klapac, Ph.D., and are under clinical guidance by Jerry Mendell, M.D., at Nationwide Children’s Hospital Center for Gene Therapy. Myonexus highlights that there are currently no approved treatments for the limb-girdle muscular dystrophies and aims to provide first-ever corrective LGMD therapies. Founded in 2017, Myonexus is headquartered in New Albany, Ohio.

Total raised

$3M

Funding rounds

1

Latest round

Seed

Latest activity

Dec 2017